Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) Director Eric I. Richman purchased 17,000 shares of the company’s stock in a transaction on Monday, July 1st. The stock was acquired at an average price of $1.22 per share, with a total value of $20,740.00. Following the completion of the purchase, the director now directly owns 289,629 shares in the company, valued at $353,347.38. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.
Gain Therapeutics Stock Performance
Gain Therapeutics stock opened at $1.12 on Tuesday. The company has a quick ratio of 2.77, a current ratio of 2.77 and a debt-to-equity ratio of 0.05. Gain Therapeutics, Inc. has a twelve month low of $1.11 and a twelve month high of $5.33. The company’s 50-day moving average price is $2.28 and its 200-day moving average price is $3.28. The company has a market cap of $20.22 million, a PE ratio of -0.75 and a beta of 0.35.
Gain Therapeutics (NASDAQ:GANX – Get Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.08. On average, equities research analysts forecast that Gain Therapeutics, Inc. will post -1.11 EPS for the current fiscal year.
Analyst Ratings Changes
Read Our Latest Analysis on GANX
About Gain Therapeutics
Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Read More
- Five stocks we like better than Gain Therapeutics
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.